Loading…
Loading…
Profitability This table compares Galera Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Eagle Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Galera Therapeutics and Eagle Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross
Eagle Pharmaceuticals (NASDAQ: EGRX - Get Free Report) and Indivior (OTCMKTS:INVVY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability. Analyst Ratings This is a breakdown of recent recommendations
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX - Get Free Report) shares passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.26 and traded as high as $0.3411. Eagle Pharmaceuticals shares last traded at $0.3411, with a volume of 104 shares. Eagle Pharmaceuticals Stock Performance The company has
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX - Get Free Report) passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.65 and traded as low as $0.38. Eagle Pharmaceuticals shares last traded at $0.38, with a volume of 9,312 shares changing hands. Eagle Pharmaceuticals Trading Up
Risk and Volatility Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Valuation and Earnings This table compares Eagle Pharmaceuticals and Aadi Bioscience"s
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Eagle Pharmaceuticals, Inc. (OTCPK: EGRX) breached their fiduciary duties to shareholders.
No recent filings indexed.